---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-26-000063"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2026-08-06T11:12:47+00:00"
generated_at: "2026-08-06T11:15:06.486182+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xeris Q2 revenue $92.1M (+29% YoY); Recorlev up 81%; tightens FY guidance to $385-390M

## Summary
- Net product revenue $91.0M (+34% YoY); Recorlev $56.8M (+81%), Gvoke $22.5M (-4%), Keveyis $11.7M (+2%).
- Net loss $31.1M includes ~$31M non-cash charge from 2028 Convertible Notes exchange; adjusted EBITDA $19.3M (+$6.7M YoY).
- Gross margin improved to 86% (Q2 2025: 82%) on favorable product mix.
- Full-year 2026 total revenue guidance tightened to $385-390M from prior range.
- USPTO Notice of Allowance for new Keveyis patent expected to extend IP protection through at least 2039.

## SEC filing metadata
- accession: 0001867096-26-000063
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2026-08-06T11:12:47+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/0001867096-26-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000063/xers-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-26-000063
- JSON: https://secwatch.observer/filing/0001867096-26-000063.json
- Plain text: https://secwatch.observer/filing/0001867096-26-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.